Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691844 · ClinicalTrials.gov registry record · Phase 2
AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
A Phase 2 study, sponsored by Amzell.
- Completed
- Registry status
- Phase 2
- Development phase
- 444
- Enrollment target
NCT03691844 is a Phase 2 study that has completed, run by Amzell. The registered enrollment target is 444 participants.
The verdict
NCT03691844, a Phase 2 study, has completed, sponsored by Amzell.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 444 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily.
Interventions
- DRUG Placebo
- DRUG Comparator
- DRUG AMZ001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03691844
The ClinicalTrials.gov registry entry for NCT03691844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amzell, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03691844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03691844 about?
NCT03691844 is a clinical study titled "AMZ001 for the Treatment of Knee Osteoarthritis Symptoms". This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily.
What is the current status of trial NCT03691844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 444 participants. The study started on 2018-10-04. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03691844?
The interventions under investigation include: Placebo (DRUG), Comparator (DRUG), AMZ001 (DRUG).
Who is sponsoring clinical trial NCT03691844?
This trial is sponsored by Amzell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.